LENZ
LENZ Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.09 / 10
Outperform
Sentiment is Outperform (6.09) and fund‑flow score 7.79 (good), with overall inflow ratio 0.49 and large‑cap inflows positive. Analyst consensus is 100% Buy from two firms, yet the stock fell 14.8% recently, creating a mismatch between expectations and price.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-10-10
InstitutionPiper Sandler
Times predicted2
Historical Win Rate50.0%
Is money flowing into or out of LENZ?
- LENZ holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.09/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
